Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROSTIN E2 vs PREPIDIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dinoprostone (PGE2) is a naturally occurring prostaglandin that stimulates uterine smooth muscle contractions and cervical ripening by binding to EP receptors, leading to increased intracellular calcium and myometrial contractility. It also promotes cervical softening through collagenase activation and glycosaminoglycan changes.
Dinoprostone (PGE2) stimulates myometrial contractions and cervical ripening by increasing intracellular calcium and promoting collagenase activity.
Induction of labor at term (FDA approved),Cervical ripening before induction of labor (FDA approved),Evacuation of uterine contents in missed abortion or intrauterine fetal death up to 28 weeks,Management of benign hydatidiform mole,Postpartum hemorrhage off-label use
Cervical ripening and induction of labor at term
Cervical ripening: 0.5 mg (1 suppository) intravaginally; repeat every 4-6 hours if needed, up to 3 doses in 24 hours. Induction of labor: 2.5 mg (1 suppository) intravaginally every 3-5 hours, maximum 10 mg/24 hours.
Intravaginal: 0.5 mg dinoprostone gel inserted into posterior vaginal fornix every 6 hours as needed for cervical ripening; maximum total dose 1.5 mg (3 doses) within 24 hours.
Terminal elimination half-life is approximately 2-3 minutes for dinoprostone due to rapid enzymatic metabolism; clinical effects are short-lived, requiring continuous infusion for sustained action.
Terminal elimination half-life: 8-12 hours (intravaginal administration).
Rapidly metabolized in the lungs, liver, and kidneys by 15-hydroxyprostaglandin dehydrogenase and prostaglandin reductase. Metabolites are excreted primarily in urine.
Rapidly metabolized via 15-hydroxyprostaglandin dehydrogenase in the lungs and other tissues; also undergoes beta-oxidation and reduction.
Primarily metabolized in the lungs, liver, and kidneys; >90% of metabolites excreted renally, with <5% unchanged in urine; minor biliary/fecal elimination.
Primarily renal: 50-70% as metabolites, 10-15% as unchanged drug; fecal: 20-30% via bile.
Approximately 80-90% bound to serum albumin.
>90% bound to albumin and α-fetoprotein.
Vd is about 0.1-0.2 L/kg, indicating limited distribution primarily to extracellular fluid; consistent with rapid clearance and small tissue binding.
~2-3 L/kg indicating extensive tissue distribution.
Intravaginal: 10-20% (due to first-pass pulmonary metabolism); intracervical: low systemic absorption (minimal bioavailability); oral: <10% due to extensive first-pass metabolism.
Intravaginal: 5-10% (uterine first-pass); oral: ~50% (extensive hepatic metabolism).
No specific dose adjustment required in renal impairment; use with caution in severe renal dysfunction (e.g., GFR <30 m L/min) due to potential for fluid retention.
No dosage adjustment required for renal impairment; use caution in severe impairment due to potential fluid retention.
No specific dose adjustment required in hepatic impairment; use with caution in severe hepatic dysfunction (Child-Pugh class C) due to altered metabolism.
No established guidelines; use caution in severe hepatic impairment (Child-Pugh class C) due to altered drug metabolism.
Not indicated for pediatric use; no established dosing guidelines.
Not indicated for pediatric use.
No specific dose adjustment required; use with caution due to increased risk of uterine hyperstimulation and cardiovascular effects in older women.
Not indicated for use in elderly patients; contraindicated in postmenopausal women.
Should be used only by trained medical personnel in a hospital setting with immediate access to facilities for managing complications such as uterine hyperstimulation, fetal distress, and emergency cesarean section.
Not to be used in women with hypersensitivity to prostaglandins, severe fetal distress, or when immediate delivery is required.
Uterine hyperstimulation may occur, leading to fetal distress or uterine rupture, especially in patients with prior cesarean section or uterine surgery.,Monitor uterine activity, fetal heart rate, and cervical status continuously during administration.,Use with caution in patients with cardiovascular, renal, or hepatic impairment.,Risk of amniotic fluid embolism, disseminated intravascular coagulation (DIC) in missed abortion cases.,Prostaglandins may cause hypotension, bronchospasm, or pyrexia.
Uterine hyperstimulation,Fetal distress,Placental abruption,Maternal hemorrhage
Known hypersensitivity to dinoprostone or other prostaglandins,Fetal distress or contraindications to vaginal delivery (e.g., cephalopelvic disproportion, abnormal fetal presentation),Uterine scar from prior cesarean section or major uterine surgery (relative contraindication due to uterine rupture risk),Placenta previa or unexplained vaginal bleeding,Grand multiparity (six or more previous term pregnancies),Acute pelvic inflammatory disease
Hypersensitivity to prostaglandins,Severe fetal distress,Chorioamnionitis,History of prior cesarean section or major uterine surgery,Cephalopelvic disproportion,Non-reassuring fetal status
No clinically significant food interactions reported. Maintain hydration and light diet as tolerated during labor.
No known food interactions. Maintain normal diet unless otherwise instructed by healthcare provider.
FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies suggest potential risk. Second and third trimesters: Used for cervical ripening and labor induction; risk of uterine hyperstimulation and fetal distress. Not associated with structural anomalies when used at term.
PREPIDIL (dinoprostone) is a prostaglandin E2 used for cervical ripening. No evidence of teratogenicity in first trimester due to lack of exposure during organogenesis; use is restricted to third trimester for induction of labor. Fetal risks include uterine hyperstimulation, fetal distress, and meconium passage. Category C: animal studies show adverse effects.
Excretion into breast milk unknown. M/P ratio not determined. Use with caution; potential for uterine contractions and adverse effects in infant. Short-term use for labor induction typically precludes breastfeeding.
Not applicable; dinoprostone is used intrapartum and rapidly metabolized, with minimal transfer to breast milk. No M/P ratio data available. Avoid breastfeeding during administration; may resume after drug washout.
No dose adjustment required; pharmacokinetics unchanged in pregnancy. Use only at term for cervical ripening and labor induction under medical supervision.
No dose adjustment required in pregnancy; pharmacokinetics not significantly altered. Use lowest effective dose to achieve cervical ripening; avoid prolonged use.
Monitor uterine contractility and fetal heart rate continuously during administration. Avoid use in patients with active pelvic inflammatory disease or hypersensitivity. Have oxytocin and tocolytics available for uterine hyperstimulation. For cervical ripening, use lowest effective dose and limit exposure to 12-24 hours.
Prepidil (dinoprostone) is a prostaglandin E2 analogue used for cervical ripening. Administer intracervically; ensure patient is in lithotomy position for insertion. Monitor uterine activity and fetal heart rate continuously. Do not use in patients with hypersensitivity to prostaglandins, severe hypertension, or known pelvic inflammatory disease. Discontinue if hyperstimulation occurs; may use terbutaline as tocolytic.
This medication is used to start or strengthen labor contractions or to soften and dilate the cervix.,You will be closely monitored during treatment for contractions and your baby's heart rate.,Report any excessive or prolonged contractions, vaginal bleeding, or severe abdominal pain immediately.,Avoid sexual intercourse and strenuous activity while using this medication.,Do not attempt to use this medication at home unless specifically instructed by your healthcare provider.
This medication is used to prepare the cervix for labor induction.,You will be monitored closely during administration.,Report any excessive or painful contractions, or bleeding.,Avoid sexual intercourse during treatment.,Inform your doctor of any allergies or medical conditions.
No interactions on record
No interactions on record
Common clinical questions about PROSTIN E2 vs PREPIDIL, answered by our medical review team.
PROSTIN E2 is a Prostaglandin Oxytocic that works by Dinoprostone (PGE2) is a naturally occurring prostaglandin that stimulates uterine smooth muscle contractions and cervical ripening by binding to EP receptors, leading to increased intracellular calcium and myometrial contractility. It also promotes cervical softening through collagenase activation and glycosaminoglycan changes.. PREPIDIL is a Prostaglandin (Oxytocic) that works by Dinoprostone (PGE2) stimulates myometrial contractions and cervical ripening by increasing intracellular calcium and promoting collagenase activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROSTIN E2 and PREPIDIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROSTIN E2 is: Cervical ripening: 0.5 mg (1 suppository) intravaginally; repeat every 4-6 hours if needed, up to 3 doses in 24 hours. Induction of labor: 2.5 mg (1 suppository) intravaginally every 3-5 hours, maximum 10 mg/24 hours.. The standard adult dose of PREPIDIL is: Intravaginal: 0.5 mg dinoprostone gel inserted into posterior vaginal fornix every 6 hours as needed for cervical ripening; maximum total dose 1.5 mg (3 doses) within 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROSTIN E2 and PREPIDIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROSTIN E2 is classified as Category C. FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies suggest potential risk. Second and third trimesters: Used for cervical ripening and labor induc. PREPIDIL is classified as Category C. PREPIDIL (dinoprostone) is a prostaglandin E2 used for cervical ripening. No evidence of teratogenicity in first trimester due to lack of exposure during organogenesis; use is rest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.